Pharmaceutical

Eli Lilly announces settlement agreement of testosterone side effects cases

Low T1 Eli Lilly announces settlement agreement of testosterone side effects casesA month before facing its first bellwether trial in a multidistrict litigation involving testosterone side effects, Eli Lilly& Co., announced it had reached a global settlement in all cases filed against it. The drug company faced claims that the company failed to warn that its testosterone replacement therapy Axiron could cause potentially deadly heart attacks, strokes and blood clots.

The pharmaceutical company told U.S. District Judge Matthew Kennelly that it had entered into a memorandum of understanding. As a result, Judge Kennelly canceled two upcoming trial dates – in January and March – involving Axiron. The trials involved the case of Tracy Garner, who claimed that using Axiron caused him to suffer a heart attack, and the case of John DeBroka Jr., who said he developed deep vein thrombosis, a blood clot in the deep veins, after taking Axiron.

The terms of the settlement were not outlined in the court documents.

Eli Lilly faced a portion of the 6,000 cases in the testosterone side effects multidistrict litigation. Other testosterone manufactures named include AbbVie and Auxilium, both of which have already gone to trial. AbbVie faced about 4,200 cases and was hit with two back-to-back verdicts totalling $290 million.

The drug companies are accused of failing to warn of testosterone side effects as well as marketing the male hormone product for an alleged off-label use – for a made up condition called “Low T.” Testosterone treatments are only indicated for men with hypogonadism, a condition in which men have low testosterone levels due to defect, disease or injury.

Source: Law360